Related Experiment Videos

Cardiopulmonary Manifestations of Collagen Vascular Diseases

Hamza Jawad1, Sebastian R McWilliams2, Sanjeev Bhalla2

  • 1Division of Diagnostic Radiology, Cardiothoracic Imaging Section, Mallinckrodt Institute of Radiology, Washington University in St. Louis, Campus Box 8131, 510 S Kingshighway Blvd, St. Louis, MO, USA. jawadh@wustl.edu.

Insights

Collagen vascular diseases commonly cause interstitial lung disease and pulmonary hypertension, impacting patient prognosis. A new classification, interstitial pneumonia with autoimmune features (IPAF), identifies patients with better outcomes than idiopathic lung disease.

Area of Science:

  • Cardiopulmonary imaging
  • Rheumatology
  • Immunology

Background:

  • Collagen vascular diseases (CVDs) encompass a group of autoimmune disorders affecting connective tissues.
  • These conditions can manifest with diverse systemic manifestations, including significant cardiopulmonary involvement.

Purpose of the Study:

  • To illustrate the cross-sectional imaging findings of cardiopulmonary complications in specific CVDs.
  • To highlight rheumatoid arthritis, scleroderma, systemic lupus erythematosus, inflammatory myopathies, and Sjögren's syndrome.

Main Methods:

  • Review of cross-sectional imaging findings in patients with diagnosed collagen vascular diseases.
  • Analysis of literature focusing on cardiopulmonary manifestations.

Main Results:

  • Interstitial lung disease (ILD) and pulmonary hypertension are the most critical cardiopulmonary complications, driving morbidity and mortality in CVDs.
  • Interstitial pneumonia with autoimmune features (IPAF) is a newly recognized entity for ILD in patients with suggestive autoimmune features, offering potentially better prognoses than idiopathic ILDs.
  • CVD patients face an elevated risk of malignancies.

Conclusions:

  • Interstitial lung disease and pulmonary hypertension are key determinants of prognosis in patients with collagen vascular diseases.
  • IPAF represents a significant advancement in classifying and managing ILD within the spectrum of autoimmune diseases.
  • Early recognition and management of cardiopulmonary complications are crucial for improving outcomes in CVD patients.
Abstract

Related Concept Videos